Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- (-) Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- (-) Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- Health Spend Management
- High-Deductible Health Plans
- (-) Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- IRA Implementation
- Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- (-) Real-World Data
- (-) Real-World Evidence
- Regulatory Barriers & Challenges
- (-) Understanding Health Spending
- (-) Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Audience
Audience
Display Only
Showing 120 Results
Specialty drug use for autoimmune conditions varies by race and wage among employees with employer-sponsored health insurance
Published in the Journal of Managed Care and Specialty Pharmacy, this study found that low-income and non-white individuals participating in commercial health plans have lower usage of specialty…
New Research Finds Commercial Health Plans' Use of Prescriber Requirements Doubled and Use of Step Therapy Increased by More Than 31% for Specialty Drug Coverage
New research co-authored by NPC examines how health plan policies have become more restrictive over time.
Characterizing Health Plan Evidence Review Practices
The study finds that some plans updated the evidence in their coverage policies for specialty medicines more often than others, and the type of evidence plans cited in their coverage policies…
Characterizing health plan evidence review practices: how often, how different, and how comprehensive?
All health care decisions should be evidence-based. Until now, it has been relatively unclear what goes into health plan evidence reviews. How frequently do health plans update their specialty drug…
Health Care Spending Effectiveness: Estimates Suggest that Spending Improved U.S. Health from 1996 to 2016
This research assessed the effectiveness of U.S. health care spending by comparing changes in health outcomes and found that, overall, innovations in health care are creating more cost-effective care…
Health Care Spending Guiding Principles
NPC established a set of principles to assess health care spending estimates and policies to ensure alignment with the goals of patient-centered care.
Patient-Centered Guiding Principles for Evaluating Health Care Spending
NPC established these principles to serve as a checklist to assess whether methods used for estimating health care spending are appropriate.
Patient-Centered Guiding Principles for Reforming Health Care to Address Rising Health Care Spending
NPC established these principles to assess health care spending policies to ensure alignment with the goals of patient-centered care.
Health Spending Post-Pandemic: Looking for High Value Beyond the Headlines
NPC Chief Science Officer Dr. Sharon Phares takes a closer look at CMS' national health expenditure report and what their predictions mean for our health care system.
Drug Price Regulation Trade-offs: Real or Imagined?
NPC hosted a panel at AcademyHealth’s National Health Policy Conference to explore the potential risks and unintended consequences of drug price regulation.
The Certainty of Uncertainty in Health Technology Assessment
A new Health Affairs Forefront article from Tufts CEVR examines the potential flaws in how health technology assessments identify and report on uncertainty.
Achieving “Fair Access” Requires Better Benefit Design
An Institute for Clinical and Economic Review report acknowledges that patients are still facing barriers to needed treatments as a result of their health benefit design.
NPC in RealClearPolicy: Price Setting Bill Is No Panacea for Patients
In a commentary for RealClearPolicy, NPC’s John M. O’Brien explains how the drug pricing deal in the Build Back Better Act could create harmful unintended consequences for patient health and the…
Digging Deeper Into Health Spending | November 2021
In this e-newsletter, NPC will dig deeper into health care spending and highlight the importance of relying on good research to create good policy.
Health Spending for Commercial Plans Is Predominantly Concentrated In Small Population of High-Intensity Consumers
NPC study finds spending on prescription drugs mirrors spending on other health care services, with a small subset of the sickest patients driving the majority of spending.
Drug Spending Mirrors Spending on Other Health Care Services
Spending on prescription drugs is not an anomaly but rather follows similar patterns as other health care services. Policy proposals that focus narrowly on constraining drug spending are…
NPC in Health Affairs: Payment Innovation Not Keeping Up
In a Health Affairs Blog article, NPC and MIT researchers outline how a new rule from CMS may fall short of what is needed to improve patient access to durable cell and gene therapies that target…
A Healthier Country Means Lower Health Care Spending
The U.S. spends twice as much per person on health care compared to other wealthy countries. While higher U.S. health care prices play a role in this disparity, they are not the only cause. A new NPC…